Attitudes toward psychedelics and psychedelic-assisted psychotherapy among Australian mental healthcare providers
Australian & New Zealand Journal of Psychiatry July 15, 2025 Zohaib Nadeem, Stephen Parker, Hugh McGovern et al. 7 citations
Background: Recent regulatory changes in Australia have approved 3,4-methylenedioxymethamphetamine for treating post-traumatic stress disorder and psilocybin for treatment-resistant depression. However, limited data exists on Australian mental healthcare providers’ attitudes, knowledge and readiness to implement with psychedelic-assisted psychotherapy. Methods: A cross-sectional survey was...
DOI: 10.1177/00048674251346679 (opens in new tab)
Psilocybin
Mental healthcare
Health care
Psychotherapist